In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...
M&As are stressful for multiple reasons, including role changes and getting laid off when staffs combine. Two talent experts ...
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
Looking for a biopharma job in New Jersey? Check out the BioSpace list of eight companies hiring life sciences professionals ...
The U.S. Court of Federal Claims ruled that Vanda cannot claim a breach of confidentiality for specifications that it did not ...
Turn your career aspirations into reality with this step-by-step guide to creating and implementing a strategic professional ...
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.
Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a ...
The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few months later.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback